Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer
FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers. Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testi...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2019-11, Vol.33 (6), p.1935-1940 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1940 |
|---|---|
| container_issue | 6 |
| container_start_page | 1935 |
| container_title | In vivo (Athens) |
| container_volume | 33 |
| creator | Hauser, Stefan Kaminski, Annette Syring, Isabella Holdenrieder, Stefan Dieckmann, Klaus-Peter Muller, Stefan C Ellinger, Jorg |
| description | FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers.
Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancer patients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men.
Serum FGF-2, HGF and PTN levels did not differ in cancer patients and healthy males within the screening cohort, whereas MIF was significantly increased among cancer patients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters.
FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancer patients. |
| doi_str_mv | 10.21873/invivo.11688 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6899099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2310657296</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-a63cabf4b7aa711712df7e98bba3b6bf43c54ed53291c69191ba56f629fba8153</originalsourceid><addsrcrecordid>eNpVkc1P3DAQxS1EBVvg2GvlI5UI9djrr0sluiILEgUkFrU3y_E6xW0Sg52s1P--FktROc3hvXkzTz-EPgA5paAk-xyGTdjEUwCh1A6agdRQST7Xu2hGKFeV4vBjH73P-RchQhJC99A-AyEop3SG_PnGdpMdQxxwbPGdT1OPv4bY2_Tbp4yP62Vd0RN8saxP8LfLGtthjW9X159wGPBt2fPDmPH3MD7glc9jcFNnE1761OOF7zq8sIPz6RC9a22X_dHLPED39flqcVFd3SwvF2dXlWNKjpUVzNmmnTfSWgkgga5b6bVqGssaUQTm-NyvOaManNCgobFctILqtrEKODtAX7a5j1PT-7UrzyXbmccUSp8_Jtpg3ipDeDA_48YIpTXRugQcvwSk-DSVQqYP2ZUidvBxyoYyIIJLqkWxVlurSzHn5NvXM0DMMxqzRWOe0RT_x_9_e3X_Y8H-Akagiq0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2310657296</pqid></control><display><type>article</type><title>Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Hauser, Stefan ; Kaminski, Annette ; Syring, Isabella ; Holdenrieder, Stefan ; Dieckmann, Klaus-Peter ; Muller, Stefan C ; Ellinger, Jorg</creator><creatorcontrib>Hauser, Stefan ; Kaminski, Annette ; Syring, Isabella ; Holdenrieder, Stefan ; Dieckmann, Klaus-Peter ; Muller, Stefan C ; Ellinger, Jorg</creatorcontrib><description>FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers.
Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancer patients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men.
Serum FGF-2, HGF and PTN levels did not differ in cancer patients and healthy males within the screening cohort, whereas MIF was significantly increased among cancer patients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters.
FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancer patients.</description><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>DOI: 10.21873/invivo.11688</identifier><identifier>PMID: 31662522</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Adolescent ; Adult ; Aged ; Biomarkers, Tumor - blood ; Carrier Proteins - blood ; Cohort Studies ; Cytokines - blood ; Fibroblast Growth Factor 2 - blood ; Hepatocyte Growth Factor - blood ; Humans ; Macrophage Migration-Inhibitory Factors - blood ; Male ; Middle Aged ; Neoplasms, Germ Cell and Embryonal - blood ; Testicular Neoplasms - blood ; Young Adult</subject><ispartof>In vivo (Athens), 2019-11, Vol.33 (6), p.1935-1940</ispartof><rights>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright 2019, International Institute of Anticancer Research 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-a63cabf4b7aa711712df7e98bba3b6bf43c54ed53291c69191ba56f629fba8153</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899099/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899099/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31662522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hauser, Stefan</creatorcontrib><creatorcontrib>Kaminski, Annette</creatorcontrib><creatorcontrib>Syring, Isabella</creatorcontrib><creatorcontrib>Holdenrieder, Stefan</creatorcontrib><creatorcontrib>Dieckmann, Klaus-Peter</creatorcontrib><creatorcontrib>Muller, Stefan C</creatorcontrib><creatorcontrib>Ellinger, Jorg</creatorcontrib><title>Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers.
Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancer patients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men.
Serum FGF-2, HGF and PTN levels did not differ in cancer patients and healthy males within the screening cohort, whereas MIF was significantly increased among cancer patients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters.
FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancer patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carrier Proteins - blood</subject><subject>Cohort Studies</subject><subject>Cytokines - blood</subject><subject>Fibroblast Growth Factor 2 - blood</subject><subject>Hepatocyte Growth Factor - blood</subject><subject>Humans</subject><subject>Macrophage Migration-Inhibitory Factors - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms, Germ Cell and Embryonal - blood</subject><subject>Testicular Neoplasms - blood</subject><subject>Young Adult</subject><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1P3DAQxS1EBVvg2GvlI5UI9djrr0sluiILEgUkFrU3y_E6xW0Sg52s1P--FktROc3hvXkzTz-EPgA5paAk-xyGTdjEUwCh1A6agdRQST7Xu2hGKFeV4vBjH73P-RchQhJC99A-AyEop3SG_PnGdpMdQxxwbPGdT1OPv4bY2_Tbp4yP62Vd0RN8saxP8LfLGtthjW9X159wGPBt2fPDmPH3MD7glc9jcFNnE1761OOF7zq8sIPz6RC9a22X_dHLPED39flqcVFd3SwvF2dXlWNKjpUVzNmmnTfSWgkgga5b6bVqGssaUQTm-NyvOaManNCgobFctILqtrEKODtAX7a5j1PT-7UrzyXbmccUSp8_Jtpg3ipDeDA_48YIpTXRugQcvwSk-DSVQqYP2ZUidvBxyoYyIIJLqkWxVlurSzHn5NvXM0DMMxqzRWOe0RT_x_9_e3X_Y8H-Akagiq0</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Hauser, Stefan</creator><creator>Kaminski, Annette</creator><creator>Syring, Isabella</creator><creator>Holdenrieder, Stefan</creator><creator>Dieckmann, Klaus-Peter</creator><creator>Muller, Stefan C</creator><creator>Ellinger, Jorg</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191101</creationdate><title>Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer</title><author>Hauser, Stefan ; Kaminski, Annette ; Syring, Isabella ; Holdenrieder, Stefan ; Dieckmann, Klaus-Peter ; Muller, Stefan C ; Ellinger, Jorg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-a63cabf4b7aa711712df7e98bba3b6bf43c54ed53291c69191ba56f629fba8153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carrier Proteins - blood</topic><topic>Cohort Studies</topic><topic>Cytokines - blood</topic><topic>Fibroblast Growth Factor 2 - blood</topic><topic>Hepatocyte Growth Factor - blood</topic><topic>Humans</topic><topic>Macrophage Migration-Inhibitory Factors - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms, Germ Cell and Embryonal - blood</topic><topic>Testicular Neoplasms - blood</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hauser, Stefan</creatorcontrib><creatorcontrib>Kaminski, Annette</creatorcontrib><creatorcontrib>Syring, Isabella</creatorcontrib><creatorcontrib>Holdenrieder, Stefan</creatorcontrib><creatorcontrib>Dieckmann, Klaus-Peter</creatorcontrib><creatorcontrib>Muller, Stefan C</creatorcontrib><creatorcontrib>Ellinger, Jorg</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hauser, Stefan</au><au>Kaminski, Annette</au><au>Syring, Isabella</au><au>Holdenrieder, Stefan</au><au>Dieckmann, Klaus-Peter</au><au>Muller, Stefan C</au><au>Ellinger, Jorg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>33</volume><issue>6</issue><spage>1935</spage><epage>1940</epage><pages>1935-1940</pages><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers.
Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancer patients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men.
Serum FGF-2, HGF and PTN levels did not differ in cancer patients and healthy males within the screening cohort, whereas MIF was significantly increased among cancer patients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters.
FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancer patients.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>31662522</pmid><doi>10.21873/invivo.11688</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0258-851X |
| ispartof | In vivo (Athens), 2019-11, Vol.33 (6), p.1935-1940 |
| issn | 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6899099 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adolescent Adult Aged Biomarkers, Tumor - blood Carrier Proteins - blood Cohort Studies Cytokines - blood Fibroblast Growth Factor 2 - blood Hepatocyte Growth Factor - blood Humans Macrophage Migration-Inhibitory Factors - blood Male Middle Aged Neoplasms, Germ Cell and Embryonal - blood Testicular Neoplasms - blood Young Adult |
| title | Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T22%3A52%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Serum%20Biomarkers%20(FGF-2,%20HGF,%20MIF%20and%20PTN)%20in%20Patients%20With%20Testicular%20Germ%20Cell%20Cancer&rft.jtitle=In%20vivo%20(Athens)&rft.au=Hauser,%20Stefan&rft.date=2019-11-01&rft.volume=33&rft.issue=6&rft.spage=1935&rft.epage=1940&rft.pages=1935-1940&rft.issn=0258-851X&rft.eissn=1791-7549&rft_id=info:doi/10.21873/invivo.11688&rft_dat=%3Cproquest_pubme%3E2310657296%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2310657296&rft_id=info:pmid/31662522&rfr_iscdi=true |